Pharmacyte Biotech Stock Filter Stocks by Fundamentals
PMCB Stock | USD 2.12 0.03 1.40% |
PharmaCyte Biotech fundamentals help investors to digest information that contributes to PharmaCyte Biotech's financial success or failures. It also enables traders to predict the movement of PharmaCyte Stock. The fundamental analysis module provides a way to measure PharmaCyte Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to PharmaCyte Biotech stock.
PharmaCyte | Shares Owned by Institutions |
PharmaCyte Biotech Current Valuation Drivers
We derive many important indicators used in calculating different scores of PharmaCyte Biotech from analyzing PharmaCyte Biotech's financial statements. These drivers represent accounts that assess PharmaCyte Biotech's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of PharmaCyte Biotech's important valuation drivers and their relationship over time.
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Market Cap | 34.3M | 39.7M | 36.2M | 56.9M | 51.2M | 27.8M | |
Enterprise Value | 33.5M | 37.6M | (49.2M) | (11.1M) | (10.0M) | (9.5M) |
PharmaCyte Biotech Institutional Holders
Institutional Holdings refers to the ownership stake in PharmaCyte Biotech that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of PharmaCyte Biotech's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing PharmaCyte Biotech's value.Shares | Susquehanna International Group, Llp | 2023-12-31 | 22 K | Northern Trust Corp | 2023-12-31 | 19.3 K | Bank Of New York Mellon Corp | 2023-12-31 | 16.6 K | Squarepoint Ops Llc | 2023-12-31 | 14.8 K | Acadian Asset Management Llc | 2023-12-31 | 4.8 K | Tower Research Capital Llc | 2023-12-31 | 1.9 K | Advisor Group Holdings, Inc. | 2023-12-31 | 1.8 K | Cwm, Llc Duplicate | 2023-12-31 | 954 | Aspire Private Capital, Llc | 2023-12-31 | 800 | K2 Principal Fund Lp | 2023-12-31 | 304.6 K | Geode Capital Management, Llc | 2023-12-31 | 215.6 K |
PharmaCyte Fundamentals
Return On Equity | -0.0174 | ||||
Return On Asset | -0.0524 | ||||
Current Valuation | (20.54 M) | ||||
Shares Outstanding | 8.45 M | ||||
Shares Owned By Insiders | 8.11 % | ||||
Shares Owned By Institutions | 15.05 % | ||||
Number Of Shares Shorted | 45.73 K | ||||
Price To Earning | 9.57 X | ||||
Price To Book | 0.60 X | ||||
EBITDA | (4.32 M) | ||||
Net Income | (4.32 M) | ||||
Cash And Equivalents | 82.23 M | ||||
Cash Per Share | 3.96 X | ||||
Total Debt | 3.34 K | ||||
Current Ratio | 75.51 X | ||||
Book Value Per Share | 3.68 X | ||||
Cash Flow From Operations | (3.79 M) | ||||
Short Ratio | 0.98 X | ||||
Earnings Per Share | (1.48) X | ||||
Beta | -0.16 | ||||
Market Capitalization | 17.84 M | ||||
Total Asset | 73.28 M | ||||
Retained Earnings | (115.96 M) | ||||
Working Capital | 67.56 M | ||||
Current Asset | 1.6 M | ||||
Current Liabilities | 449 K | ||||
Net Asset | 73.28 M |
About PharmaCyte Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze PharmaCyte Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PharmaCyte Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PharmaCyte Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as PharmaCyte Biotech using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out PharmaCyte Biotech Piotroski F Score and PharmaCyte Biotech Altman Z Score analysis. For information on how to trade PharmaCyte Stock refer to our How to Trade PharmaCyte Stock guide.Note that the PharmaCyte Biotech information on this page should be used as a complementary analysis to other PharmaCyte Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for PharmaCyte Stock analysis
When running PharmaCyte Biotech's price analysis, check to measure PharmaCyte Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PharmaCyte Biotech is operating at the current time. Most of PharmaCyte Biotech's value examination focuses on studying past and present price action to predict the probability of PharmaCyte Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PharmaCyte Biotech's price. Additionally, you may evaluate how the addition of PharmaCyte Biotech to your portfolios can decrease your overall portfolio volatility.
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |
Is PharmaCyte Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PharmaCyte Biotech. If investors know PharmaCyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PharmaCyte Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.48) | Return On Assets (0.05) | Return On Equity (0.02) |
The market value of PharmaCyte Biotech is measured differently than its book value, which is the value of PharmaCyte that is recorded on the company's balance sheet. Investors also form their own opinion of PharmaCyte Biotech's value that differs from its market value or its book value, called intrinsic value, which is PharmaCyte Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PharmaCyte Biotech's market value can be influenced by many factors that don't directly affect PharmaCyte Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PharmaCyte Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if PharmaCyte Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PharmaCyte Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.